Company research
Seres Therapeutics, Inc.
CIK 1609809Updated Sep 27, 2026
SecurityMCRB · NASDAQ · equity
Name history
Seres Therapeutics, Inc. · through Aug 21, 2026Seres Health, Inc. · through May 14, 2015
MCRB price & chart
Loading TradingView…
NASDAQ:MCRB on TradingView ↗About the company
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products (LBP), designed to address unmet needs in oncology that can lead to interruption to patients’ cancer care and/or mortality, and to treat inflammatory and immune (I&I) diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal (GI) tract. The Company previously led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, an investigational cultivated multi-strain biotherapeutic, which has received Breakthrough Therapy and Fast Track designations, is being advanced for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT), and is Phase 2 ready, pending receipt of funding. SER-155 is also being developed to address immune checkpoint inhibitor-related enterocolitis (irEC) to provide an immunosuppressive-free alternative and enab…
In the news
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference ↗
Seeking Alpha
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis - Slideshow ↗
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript ↗
Seres Therapeutics GAAP EPS of $0.64, revenue of $0.78M ↗
Recent filings
EFFECT filing
4 filing
S-3 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 138,193,000Source | 139,810,000Source | 358,600,000Source | 348,784,000Source |
| Property, Plant and Equipment, NetUSD | 7,635,000Source | 11,534,000Source | 22,457,000Source | 22,985,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 45,766,000Source | 30,793,000Source | 127,965,000Source | 163,030,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 157,000Source | — | — | — |
| Inventory, NetUSD | — | — | 29,647,000Source | — |
| Assets, CurrentUSD | 49,376,000Source | 38,674,000Source | 175,410,000Source | 194,764,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,093,000Source | 5,813,000Source | 9,124,000Source | 13,423,000Source |
| Operating Lease, Right-of-Use AssetUSD | 72,483,000Source | 80,903,000Source | 109,793,000Source | 110,984,000Source |
| Other Assets, NoncurrentUSD | 31,000Source | 31,000Source | 41,354,000Source | 10,465,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 93,975,000Source | 126,026,000Source | 403,456,000Source | 338,001,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 10,000Source | 173,000Source | 135,000Source | 125,000Source |
| Retained Earnings (Accumulated Deficit)USD | -972,403,000Source | -978,099,000Source | -978,235,000Source | -864,511,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | 0Source | -12,000Source |
| Stockholders' Equity Attributable to ParentUSD | 44,218,000Source | 13,784,000Source | -44,856,000Source | 10,783,000Source |
| Additional Paid in Capital, Common StockUSD | 1,016,611,000Source | 991,710,000Source | 933,244,000Source | 875,181,000Source |
| Liabilities and EquityUSD | 138,193,000Source | 139,810,000Source | 358,600,000Source | 348,784,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 19,322,000Source | 41,222,000Source | 98,659,000Source | 85,596,000Source |
| Operating Lease, Liability, CurrentUSD | 10,390,000Source | 8,674,000Source | 6,677,000Source | 3,601,000Source |
| Accounts Payable, CurrentUSD | 1,682,000Source | 4,079,000Source | 3,641,000Source | 17,440,000Source |
| Operating Lease, Liability, NoncurrentUSD | 72,576,000Source | 82,966,000Source | 105,715,000Source | 107,942,000Source |
| Other Liabilities, NoncurrentUSD | 2,077,000Source | 1,838,000Source | 1,628,000Source | 1,442,000Source |
| Additional Financial Items | ||||
| Long-term DebtUSD | — | — | 110,000,000Source | 50,000,000Source |
| Short-term InvestmentsUSD | — | — | 0Source | 18,311,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 4,133,000Source | 5,468,000Source | 6,243,000Source | 6,629,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,840,000Source | 20,971,000Source | 34,101,000Source | 25,482,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 157,000Source | — | 0Source | 0Source |
| Increase (Decrease) in InventoriesUSD | 0Source | 33,795,000Source | 29,647,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | -2,397,000Source | -2,940,000Source | -11,578,000Source | 2,203,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 1,117,000Source | -148,609,000Source | -117,354,000Source | -228,816,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -42,000Source | 142,293,000Source | 10,582,000Source | 82,428,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 252,000Source | 380,000Source | 7,975,000Source | 9,821,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 13,898,000Source | -90,372,000Source | 71,705,000Source | 129,602,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 54,434,000Source | 39,461,000Source | 136,150,000Source | 171,215,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 10,858,000Source | 12,547,000Source | 4,926,000Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,840,000Source | 20,971,000Source | 34,101,000Source | 25,482,000Source |
| Amortization of Debt Issuance CostsUSD | 0Source | 1,413,000Source | 1,139,000Source | 705,000Source |
| Gain (Loss) on Disposition of BusinessUSD | 0Source | 146,707,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 192,000Source | -317,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -23,351,000Source | -1,625,000Source | — |
| General and Administrative ExpenseUSD | 39,156,000Source | 53,183,000Source | 87,744,000Source | 79,694,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | 5,696,000Source | -125,771,000Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 0Source | 125,907,000Source | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Inventory Write-downUSD | — | — | 0Source | — |
| Investment Income, InterestUSD | 2,227,000Source | 3,967,000Source | 7,301,000Source | 3,058,000Source |
| Net Income (Loss) Attributable to ParentUSD | 5,696,000Source | 136,000Source | -113,724,000Source | -250,157,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 5,696,000Source | — | — | -250,157,000Source |
| Nonoperating Income (Expense)USD | 99,667,000Source | -4,456,000Source | -5,741,000Source | -3,667,000Source |
| Operating ExpensesUSD | 94,760,000Source | 121,315,000Source | 234,308,000Source | 253,618,000Source |
| Other Nonoperating Income (Expense)USD | 16,755,000Source | -14,107,000Source | 134,000Source | -705,000Source |
| Payments to Acquire InvestmentsUSD | 0Source | 0Source | 4,426,000Source | 48,221,000Source |
| Proceeds from Issuance of Common StockUSD | — | 0Source | 0Source | 96,721,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | 27,606,000Source |
| Proceeds from Stock Options ExercisedUSD | 501,000Source | 0Source | 877,000Source | 966,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 7,128,000Source |
| Operating Income (Loss)USD | -93,971,000Source | -121,315,000Source | -107,983,000Source | -246,490,000Source |
| Other Nonoperating Income (Expense)USD | 16,755,000Source | -14,107,000Source | 134,000Source | -705,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | 5,696,000Source | 136,000Source | -113,724,000Source | -250,157,000Source |
| Earnings Per Share, BasicUSD per share | 0.64Source | 0Source | -0.89Source | -2.31Source |
| Earnings Per Share, DilutedUSD per share | 0.64Source | 0Source | -0.89Source | -2.31Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 8,858,975Source | 155,400,760Source | 128,003,294Source | 108,077,043Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 8,869,742Source | 155,400,760Source | 128,003,294Source | 108,077,043Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 39,156,000Source | 53,183,000Source | 87,744,000Source | 79,694,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | 5,696,000Source | -125,771,000Source | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | 0.64Source | -0.81Source | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | 0.64Source | -0.81Source | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 0Source | 125,907,000Source | — | — |
| Interest Expense, DebtUSD | 0Source | 0Source | 13,176,000Source | 6,020,000Source |
| Investment Income, InterestUSD | 2,227,000Source | 3,967,000Source | 7,301,000Source | 3,058,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 5,696,000Source | — | — | -250,157,000Source |
| Nonoperating Income (Expense)USD | 99,667,000Source | -4,456,000Source | -5,741,000Source | -3,667,000Source |
| Operating ExpensesUSD | 94,760,000Source | 121,315,000Source | 234,308,000Source | 253,618,000Source |
| Research and Development ExpenseUSD | 49,060,000Source | 64,600,000Source | 145,860,000Source | 172,920,000Source |
Filing attachments
d124829dex991.htm · 8-K · 2026-08-05
EX-99.1 2 d124829dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK) IST data supp…
Read attachment ↗d130829dex991.htm · 8-K · 2026-07-08
EX-99.1 2 d130829dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SERES THERAPEUTICS ANNOUNCES EARLY CLINICAL DATA SHOWING POTENTIAL FOR SER-155 IN IMMUNE CHECKPOINT INHIBITOR-RELATED ENTEROCOLITIS (irEC), A FREQUENT ADVERSE REACTION THAT FORCES MANY PATIENTS TO HALT CANCER TREATMENT 80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering Cancer Ce…
Read attachment ↗d130829dex992.htm · 8-K · 2026-07-08
EX-99.2 3 d130829dex992.htm EX-99.2 EX-99.2 Seres Company Overview July 2026 Seres Therapeutics, Inc. © 2026 Exhibit 99.2 Disclaimers Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: the design, timing and result…
Read attachment ↗d156701dex991.htm · 8-K · 2026-06-05
EX-99.1 4 d156701dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SERES THERAPEUTICS ANNOUNCES TWO TRANSACTIONS TO STRENGTHEN BALANCE SHEET, REDUCE OPERATING COSTS AND EXTEND PROJECTED OPERATING CASH RUNWAY WELL INTO THE FIRST QUARTER OF 2027 Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST ™ net sales-based milestones Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability …
Read attachment ↗d155025dex991.htm · 8-K · 2026-05-05
EX-99.1 2 d155025dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biotherapeutic programs in inflammatory and immune diseases Company pursuing partnerships and other sources of capital to support continued develo…
Read attachment ↗